Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Oct 01, 2015 9:26am

51 Views

Post# 24152698

RE:RE:RE:Caution

icecube wrote: I like CPH at these levels. $4.80 was a key target for me.

thedave2006 wrote: come down a long way, worth another entry? had sold all the way up and then moved out of it totally at around 9.00ish for another one in the same space.....oversold cph or not?

Why? why do you like 4.80? From a technical perspective this is not a bad buy, but this company just sucks. With the debt it has, i don't see how they anticipate generate enough free cash flow to pay that down or do additional acquisitions.

Bullboard Posts

Global Tungsten Market and Supply Security